Cantel Medical Corp. (NYSE:CMN) Chairman Charles M. Diker sold 14,897 shares of Cantel Medical Corp. stock in a transaction that occurred on Monday, October 10th. The stock was sold at an average price of $78.76, for a total transaction of $1,173,287.72. Following the completion of the sale, the chairman now directly owns 3,190,111 shares in the company, valued at approximately $251,253,142.36. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Cantel Medical Corp. (NYSE:CMN) opened at 76.65 on Wednesday. The stock has a market capitalization of $3.17 billion, a price-to-earnings ratio of 53.30 and a beta of 1.59. The company has a 50-day moving average of $77.54 and a 200-day moving average of $71.14. Cantel Medical Corp. has a 1-year low of $53.64 and a 1-year high of $81.63.

Cantel Medical Corp. (NYSE:CMN) last announced its quarterly earnings data on Thursday, September 29th. The company reported $0.48 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.11. The business had revenue of $179 million for the quarter. Cantel Medical Corp. had a net margin of 9.02% and a return on equity of 16.70%. Cantel Medical Corp.’s revenue for the quarter was up 18.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.39 EPS. Analysts anticipate that Cantel Medical Corp. will post $1.98 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Cantel Medical Corp. (NYSE:CMN)

A number of large investors have recently made changes to their positions in the company. Acrospire Investment Management LLC boosted its stake in shares of Cantel Medical Corp. by 51.2% in the second quarter. Acrospire Investment Management LLC now owns 1,477 shares of the company’s stock worth $102,000 after buying an additional 500 shares during the period. LS Investment Advisors LLC boosted its stake in Cantel Medical Corp. by 7.5% in the second quarter. LS Investment Advisors LLC now owns 1,510 shares of the company’s stock worth $104,000 after buying an additional 106 shares during the last quarter. BlackRock Inc. boosted its stake in Cantel Medical Corp. by 119.5% in the first quarter. BlackRock Inc. now owns 2,355 shares of the company’s stock worth $168,000 after buying an additional 1,282 shares during the last quarter. Bank of Montreal Can purchased a new stake in Cantel Medical Corp. during the second quarter worth approximately $203,000. Finally, Cypress Wealth Advisors LLC purchased a new stake in Cantel Medical Corp. during the first quarter worth approximately $210,000. Institutional investors and hedge funds own 81.60% of the company’s stock.

CMN has been the topic of a number of research reports. Benchmark Co. initiated coverage on shares of Cantel Medical Corp. in a report on Monday, August 29th. They issued a “buy” rating and a $83.00 price target on the stock. Needham & Company LLC initiated coverage on shares of Cantel Medical Corp. in a report on Wednesday, August 24th. They issued a “hold” rating on the stock.

Cantel Medical Corp. Company Profile

Cantel Medical Corp. is a provider of infection prevention and control products and services in the healthcare market. The Company’s segments include Endoscopy, Water Purification and Filtration, Healthcare Disposables, Dialysis and Specialty Packaging. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

5 Day Chart for NYSE:CMN

Receive News & Stock Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related stocks with our FREE daily email newsletter.